Atherosclerosis plus最新文献_第6页

Real-world efficacy and side effect profile of bempedoic acid in a tertiary centre lipid clinic 三级中心血脂诊所使用贝母皂苷的实际疗效和副作用概况

IF 1.4

Atherosclerosis plus Pub Date : 2024-09-01 DOI: 10.1016/j.athplu.2024.08.008

Kian Parsapour Moghadam * , Alessia David , Shahenaz Walji , Lucy Barton , Jaimini Cegla , Ben Jones

引用次数: 0

HMGCoAR autoantibodies: hidden in plain sight? HMGCoAR 自身抗体：隐藏在众目睽睽之下？

IF 1.4

Atherosclerosis plus Pub Date : 2024-09-01 DOI: 10.1016/j.athplu.2024.08.016

G. Mercer-Smith ∗ , F. Jenkinson , P. Banerjee , M. Abbas , C. Ferriman , R.D.G. Neely , A. Luvai

引用次数: 0

Bempedoic acid: real-world efficacy and tolerability in lipid clinics across three UK Centres 双鱼藤酸：英国三个中心血脂诊所的实际疗效和耐受性

IF 1.4

Atherosclerosis plus Pub Date : 2024-09-01 DOI: 10.1016/j.athplu.2024.08.019

A. Jakubowska ∗ , W. Al Hasani , J. Williams , Z. MacMahon , B. Balbas , M.A. Crook , A. Viljoen , T.M. Reynolds , A.S. Wierzbicki

引用次数: 0

Ketogenic Diet – a culinary delight but is there a cautionary tale? 生酮饮食--美味佳肴，但是否有警示意义？

IF 1.4

Atherosclerosis plus Pub Date : 2024-09-01 DOI: 10.1016/j.athplu.2024.08.011

R. Valaiyapathi ∗ , N. Rao , R. Chandra , R.P. Vincent , R. Ranasinghe

引用次数: 0

Variants in LPA are associated with mutation-negative Familial Hypercholesterolaemia: whole genome sequencing analysis in the 100,000 Genomes Project LPA变异与突变阴性家族性高胆固醇血症有关：十万基因组计划的全基因组测序分析

IF 1.4

Atherosclerosis plus Pub Date : 2024-09-01 DOI: 10.1016/j.athplu.2024.08.015

Martin Bird , Antoine Rimbert , Alan M. Pittman , Steve E. Humphries , Marta Futema ∗

引用次数: 0

A tale of 2 pregnancies: the biochemical trends, medical management, and outcomes of hypertriglyceridemia in pregnancy secondary to multi-factorial chylomicronaemia syndrome (MCS) and extreme ketogenic/carnivorous diet 两次妊娠的故事：继发于多因素乳糜泻综合征（MCS）和极端生酮/肉食饮食的妊娠高甘油三酯血症的生化趋势、医疗管理和结果

IF 1.4

Atherosclerosis plus Pub Date : 2024-09-01 DOI: 10.1016/j.athplu.2024.08.003

N.W.P. Cantley ∗ , S. Tapley , K. Antwi , P. Downie , E. Willis

引用次数: 0

Lomitapide in paediatric patients with homozygous familial hypercholesterolaemia (HoFH) – Analysis of patient-level LDL-C reduction, fat-soluble vitamins, lipoproteins and patient maturation from the APH-19 study 洛美他匹在同型家族性高胆固醇血症（HoFH）儿科患者中的应用--APH-19 研究对患者低密度脂蛋白胆固醇（LDL-C）降低、脂溶性维生素、脂蛋白和患者成熟度的分析

IF 1.4

Atherosclerosis plus Pub Date : 2024-09-01 DOI: 10.1016/j.athplu.2024.08.020

Luis Masana , Alberto Zambon , Claus Peter Schmitt , Christina Taylan , Joenna Driemeyer , Hofit Cohen , Paola Sabrina Buonuomo , Abdullah Alashwal , Mohammed Al-Dubayee , José Luis Diaz-Diaz , Faouzi Maatouk , Sergio Martinez-Hervas , Brian Mangal , Naji Kholaif , Sandra Löwe , Zsuzsanna Tamas ∗

引用次数: 0

Genetic Landscape of Familial Chylomicronaemia Syndrome (FCS) and Multifactorial Chylomicronaemia Syndrome (MCS) in United Kingdom 英国家族性乳糜微粒血症综合征（FCS）和多因素乳糜微粒血症综合征（MCS）的遗传情况

IF 1.4

Atherosclerosis plus Pub Date : 2024-09-01 DOI: 10.1016/j.athplu.2024.08.013

Bilal Bashir , Natalie Forrester , Paul Downie , Carolyn Dent , Dawn O’Sullivan , Sarah Marsh , Raabya Pasha , Anoushka Kamath , Haya Haso , Maryam Ferdousi , Jian Wang , Robert Hegele , Handrean Soran

引用次数: 0

Extreme founder effect associated with hyperglycemia and hyperlipidemia on the island of NIAS/Indonesia 印度尼西亚尼亚斯岛上与高血糖和高脂血症有关的极端奠基效应

IF 1.4

Atherosclerosis plus Pub Date : 2024-07-23 DOI: 10.1016/j.athplu.2024.07.002

Ingo Kennerknecht , Johannes M. Hämmerle , Manfred Fobker , Jerzy-Roch Nofer

{"title":"Extreme founder effect associated with hyperglycemia and hyperlipidemia on the island of NIAS/Indonesia","authors":"Ingo Kennerknecht , Johannes M. Hämmerle , Manfred Fobker , Jerzy-Roch Nofer","doi":"10.1016/j.athplu.2024.07.002","DOIUrl":"10.1016/j.athplu.2024.07.002","url":null,"abstract":"<div><p>The island of Nias/Indonesia shows an extremely reduced genetic diversity indicating a strong founder effect. As a consequence, the prevalence of some disease genes should significantly differ among populations depending on the gene pool passed on to the founder population and their successive expansion as it has already been documented for several monogenic diseases. Results of the current study based on routine laboratory blood examination give rise to the notion that this might also hold true for polygenic disorders. We observed very high prevalence of hyperglycemia (non-fasting glucose above 200 mg/dL in 14 % Nias population compared to 1.5 % in the population of the neighboring island of Sumatra) accompanied by hypertriglyceridemia, high non-HDL-cholesterol, and low HDL-cholesterol levels. These findings suggest that the Nias population may be disproportionally affected by prediabetes and type 2 diabetes mellitus. By contrast, laboratory parameters potentially indicative of other polygenic disorders such as total plasma cholesterol, electrolytes, creatinine, urea, and uric acid were comparable between the inhabitants of Nias and Sumatra islands. To our knowledge this is the first study suggesting that the extremely strong genetic bottleneck seen in the Nias population translates into the widespread metabolic disease with potentially deleterious influence on public health.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"57 ","pages":"Pages 26-29"},"PeriodicalIF":1.4,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667089524000178/pdfft?md5=308d0b8c2f1c0734c601c409bf9639ac&pid=1-s2.0-S2667089524000178-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Associations of very low Lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver disease 极低脂蛋白（a）水平与新发糖尿病和非酒精性肝病风险的关系

IF 1.4

Atherosclerosis plus Pub Date : 2024-07-11 DOI: 10.1016/j.athplu.2024.07.001

Ming Wai Yeung , M. Abdullah Said , Yordi J. van de Vegte , Niek Verweij , Robin P.F. Dullaart , Pim van der Harst

{"title":"Associations of very low Lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver disease","authors":"Ming Wai Yeung , M. Abdullah Said , Yordi J. van de Vegte , Niek Verweij , Robin P.F. Dullaart , Pim van der Harst","doi":"10.1016/j.athplu.2024.07.001","DOIUrl":"https://doi.org/10.1016/j.athplu.2024.07.001","url":null,"abstract":"<div><h3>Background and aims</h3><p>We aimed to study the association of very low serum Lipoprotein(a) [Lp(a)] concentrations with new-onset type 2 diabetes (T2D) and non-alcoholic liver disease (NAFLD) in the context of statin usage in the UK Biobank, a large prospective population cohort.</p></div><div><h3>Methods</h3><p>Using an extended biomarker dataset, we identified 47,362 participants with very low Lp(a) concentrations (<3.8 nmol/L) from a total of 451,479 participants. With a median follow-up of 12.3 years, we assessed the risk of new-onset cardiometabolic diseases in participants stratified by statin usage with Cox proportional hazards models. We performed two-sample Mendelian randomization MR analyses to test causal relationship between genetically predicted Lp(a) and T2D and NAFLD.</p></div><div><h3>Results</h3><p>Taking the participants with Lp(a) within reportable range as the reference group, the hazard ratios (HR) for T2D were 1.07 (95 % confidence interval, CI 1.01–1.13) and for NAFLD 1.30 (95 % CI 1.20–1.41) respectively for participants with very low Lp(a) (<3.8 nmol/L). The risk for new-onset T2D was higher in participants using statins (adjusted HR 1.15; 95 % CI 1.05–1.27). The risk estimates for new-onset NAFLD were comparable in the analysis stratified by statin use. There was no evidence for causal links between genetically predicted Lp(a) and T2D nor NAFLD in two-sample MR analyses.</p></div><div><h3>Conclusions</h3><p>Very low Lp(a) was associated with higher risks of T2D and NAFLD in a prospective analysis of the UK Biobank. The association with T2D was influenced by lipid lowering medication usage. MR analyses did not support causality for these inverse associations.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"57 ","pages":"Pages 19-25"},"PeriodicalIF":1.4,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667089524000166/pdfft?md5=c3a6777b13986ebec4c5e9321f64810d&pid=1-s2.0-S2667089524000166-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141607836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0